Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampicin on BI 894416 PK in Healthy Males
NCT04060719Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 894416 in asthma (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 Extrapolated to Infinity at 48 hours and Maximum Measured Concentration of BI 894416 in Plasma at 48 hours. Started Sep 2019; status: completed.
02
Drugs
BI 894416
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04060719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04060719.